In healthcare, the transformation journey from managing spend to achieving outcomes often takes a circuitous route, with processes acting as detours rather than advancements. But for Providence, the visions of a systemwide pharmacy network provided the most direct path to optimizing pharmacy operation performance across the entire organization.

Structure was a key value accelerator for Providence. The health system began its pharmacy optimization process in July 2019, and between February and August 2020 alone, the system saved more than $8.5 million in drug spend while simultaneously improving drug-related clinical outcomes for patients.

A Network Platform for Change

Providence is a seven-state health system built by a series of hospital and health system acquisitions, consolidations, mergers and partnerships over a period of nearly two decades.
Until recently, each component hospital and regional health system’s pharmacy operations and drug purchasing practices acted independently. As a result, the organization lacked a standardized drug formulary, drug purchasing contracts and processes. This led to inefficiencies in pharmacy workflows, overspending on pharmaceuticals and disparate pharmacy management and drug inventory IT systems. The net impact was two-fold:

“I’ve seen a 52%–71% increase in the rate of adoption of four biosimilars to increase bone marrow production of white blood cells.”

Rodrigo Giraldo
Director for Pharmacy Contracting and Supply Chain, Providence

$2.7M
Savings from consolidate flu vaccine purchases for 2020-2021 flu season

$10.4M
Annualized savings by converting to biosimilar Udenyca from biologic Neulasta to increase bone marrow production of white blood cells

$27M
Savings across seven molecules in two years using biosimilars

Network Platform Supports New Structures
The Providence pharmacy network installed by Bahou and his team of network system leaders in 2020 supports several new structures that ensure that the system’s 53 hospitals, 1,085 outpatient clinics, and 33,000 employed and affiliated physicians follow the same processes when it comes to drug purchasing, formulary management and prescribing practices.

52%–71%
Biosimilar adoption rates for four biosimilar drugs by prescribing physicians

slowing down pharmacy operations’ ability to deliver patient value and exposing Providence to competitive threats from vertical integration.

To take the organization in a different direction, Elie Bahou, senior vice president and chief pharmacy officer, had a plan. Working with Vizient®, Bahou and his pharmacy team created the Providence Health Pharmacy Network to oversee pharmacy operations across the entire system. Instead of acting as 53 separate entities, the hospitals and clinics would now act as one unit.

“The first step was to optimize our combined $2.5 billion in drug spend through formulary alignment. What this meant was to bring our inpatient and outpatient pharmacies under the leadership of our system pharmacy,” he says.

CASE STUDY
Providence

52%–71%
Biosimilar adoption rates for four biosimilar drugs by prescribing physicians

$2.7M
Savings from consolidate flu vaccine purchases for 2020-2021 flu season

$10.4M
Annualized savings by converting to biosimilar Udenyca from biologic Neulasta to increase bone marrow production of white blood cells

$27M
Savings across seven molecules in two years using biosimilars

Network Platform Supports New Structures
The Providence pharmacy network installed by Bahou and his team of network system leaders in 2020 supports several new structures that ensure that the system’s 53 hospitals, 1,085 outpatient clinics, and 33,000 employed and affiliated physicians follow the same processes when it comes to drug purchasing, formulary management and prescribing practices.
We take two approaches. A soft approach, which is working directly with our physicians, to understand their needs, their challenges, their concerns and get their buy-in,” says Rodrigo Giraldo, director, pharmacy contracting and supply chain. “Then there’s the hard approach, which is using technology, like our EHR system, to drive compliance and implement drug conversion opportunities.”

Clinical Governance, Collaboration and Cost Reduction

The network-wide pharmacy infrastructure put in by Bahou, his team and Vizient helped Providence reach the first three stops on Bahou’s “roadmap to success”: consolidation, modernization and standardization. By reaching those initial destinations successfully, Providence gained three critical capabilities it didn’t have: clinical governance, collaboration and cost reduction.

Clinical Governance

At most hospitals and health systems, physicians often lead formulary decisions, including key roles on pharmacy and therapeutics committees that drive these drug purchasing and usage decisions. At Providence, under the new structures, pharmacists and doctors work hand-in-glove to make data-driven formulary decisions based on clinical need, drug effectiveness and cost.

Collaboration

The new internal network design creates pathways for the system leadership team to easily collaborate and communicate pharmacy initiatives to purchasing and prescribing sites in all seven regions.
They also create new pathways for individual hospitals, clinics and prescribers to share best practices with peers across the system.

**Cost Reduction**

The most obvious benefit of the new network design is the ability to reduce Providence’s drug spend while simultaneously making clinical improvements in terms of drug efficacy and availability and doing both quickly. Savings emanate from leveraging the group purchasing power of 53 hospitals and single-sourcing purchases from one manufacturer. Savings also come from drug conversions such as switching from higher-cost biologics to lower-cost but equally effective biosimilars. The Providence team implemented seven biosimilar based utilization management (UM) initiatives in the past two years, saving $27 million across seven molecules in two years. “Our new analytics capabilities gave us visibility into how much we were spending on biologics and how we could begin replacing them with low-cost alternative biosimilars,” says Sophia Humphreys, director, system pharmacy clinical services.

**Roadmap to Success**

Providence’s achievements would not be possible without the processes created by the new systemwide pharmacy network.

For example, the biggest barrier to the changes advocated by Bahou and his team aren’t the changes themselves but rather resistance to changes in drug prescribing practices and drug purchasing habits at individual hospitals and by individual physicians.

The new network-enabled structures and practices essentially act as a systemwide pharmacy change management vehicle to move Providence where it needs to go in terms of organization and purchasing powering for its pharmacy operations.

Bahou and his team are now focusing on the final two destinations on his “roadmap to success”: insulating Providence from the ill effects of vertical integration by competitors and new market entrants, and growing Providence’s inpatient and outpatient pharmacy operations in all seven of the system’s regions.

—Elie Bahou, Senior Vice President and Chief Pharmacy Officer, Providence
CASE STUDY

Providence

© 2021 Vizient, Inc. All rights reserved.

For more information on Vizient capabilities, contact us at futureofhealthcare@vizientinc.com.

As the nation’s largest member-driven health care performance improvement company, Vizient provides solutions and services that empower health care providers to deliver high-value care by aligning cost, quality and market performance. With analytics, advisory services and a robust sourcing portfolio, we help members improve patient outcomes and lower costs.

© 2021 Vizient, Inc. All rights reserved.

The reproduction or use of this document in any form or in any information storage and retrieval system is forbidden without the express, written permission of Vizient.